ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 137
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
C
D
E
F
Knowledge, attitudes and practices towards herpes zoster
(HZ) and HZ vaccination among a demographic sample of
the public in Asia
Dr Jing Chen1, Jennifer Si2, Regina Gowindah2, Vince Grillo2, Dr Raunak Parikh3, Sumitra
Shantakumar4, Felix Chan5, Macy Chan6, Won Suk Choi7, Erick Huang8, Kuo-Chin Huang9, Li-Min
Huang10, Hyungwoo Kim11, Choon Kit Leong12, Hoe-Nam Leong13, Yubin Seo14, Charles Williams15,
Andrew TY Wong16
1
Epidemiology and Health Outcomes, GSK, 2Cerner Enviza, Singapore, 3Medical Affairs, GSK, Wavre,
Value Evidence and Outcomes, GSK, 5Division of Geriatric Medicine, University Department of
Medicine, University of Hong Kong, 6Medical Affairs, GSK, 7Department of Internal Medicine, Korea
University College of Medicine, Korea University Ansan Hospital, 8Medical Affairs, GSK, 9Department
of Family Medicine, National Taiwan University Hospital Hsin-Chu Branch, 10Department of Paediatrics,
National Taiwan University Hospital, 11Medical Affairs, GSK, Seoul, 12Mission Medical Clinic, Singapore,
13
Rophi Clinic, Mount Elizabeth Novena Specialist Centre, 14Department of Internal Medicine, Kangnam
Sacred Heart Hospital, Hallym University, 15Medical Affairs, GSK, 16Infectious Diseases, Central
Medical Practice
4
G
H
I
J
K
Aim and Goals
To elicit the knowledge, attitudes and practices towards herpes zoster (HZ) disease and vaccination
among the public in selected Asia-Pacific locales, as well as identify factors influencing their HZ
vaccination perceptions and behaviour.
Methods
A cross-sectional study across Hong Kong (HK), Singapore (SG), South Korea (SK), and Taiwan
(TW) was conducted in January–September 2022. Following concept elicitation interviews with 78
individuals from a demographically representative sample, a 30-minute online survey was conducted
with the same target population: people ≥50 years of age (YOA; n = 1163), working/financially
independent adults with parents ≥50 YOA (n = 203) and HZ patients ≥50 YOA (n = 807; total n = 2173).
Descriptive analyses were used to summarise responses from the study population and findings were
presented as counts and percentages, based on categorical variables.
Results
A substantial knowledge gap existed among study participants about HZ, including its causes,
long-term impact and at-risk groups. Four in five respondents agreed that HZ has a negative effect
on patients’ quality of life and can impact activities of daily living. Awareness of the availability of
HZ vaccines varied across locales; awareness was highest in SK (76%), lowest in TW (36%) and
higher among HZ patients (73%) than HZ-naïve individuals ≥50 YOA (49%). Approximately two in
five individuals ≥50 YOA had been recommended an HZ vaccine; the proportion was lowest in TW
(27%). Key drivers of HZ vaccination included preventing disease/recurrence (44%) and long-term
complications (41%), and physician’s recommendation (36%). Respondents expressed interest towards
understanding more about HZ vaccines, including vaccine effectiveness (53%), side effects (52%) and
cost (49%).
Conclusion
Knowledge gaps surrounding HZ and HZ vaccination remain. Initiatives are needed to improve public
awareness of HZ, its complications and HZ vaccination benefits. Physicians play a crucial role in
increasing public confidence and acceptance of HZ vaccination.
135